These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 8826929)
21. Comparing histopathological classification with MYCN, 1p36 and 17q status detected by fluorescence in situ hybridisation from 14 untreated primary neuroblastomas in Singapore. Yong MH; Hwang WS; Knight LA; Fung W; Chan MY; Seow WT; Chui CH Singapore Med J; 2009 Nov; 50(11):1090-4. PubMed ID: 19960166 [TBL] [Abstract][Full Text] [Related]
22. Fluorescence in situ hybridization analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations. Spitz R; Hero B; Westermann F; Ernestus K; Schwab M; Berthold F Genes Chromosomes Cancer; 2002 Jul; 34(3):299-305. PubMed ID: 12007190 [TBL] [Abstract][Full Text] [Related]
23. Chromosome imbalances and alterations of AURKA and MYCN genes in children with neuroblastoma. Inandiklioğlu N; Yilmaz S; Demirhan O; Erdoğan S; Tanyeli A Asian Pac J Cancer Prev; 2012; 13(11):5391-7. PubMed ID: 23317189 [TBL] [Abstract][Full Text] [Related]
24. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma. Spitz R; Hero B; Ernestus K; Berthold F Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740 [TBL] [Abstract][Full Text] [Related]
25. MYCN gain and MYCN amplification in a stage 4S neuroblastoma. Noguera R; Cañete A; Pellín A; Ruiz A; Tasso M; Navarro S; Castel V; Llombart-Bosch A Cancer Genet Cytogenet; 2003 Jan; 140(2):157-61. PubMed ID: 12645655 [TBL] [Abstract][Full Text] [Related]
26. Identification of MYCN gene amplification in neuroblastoma using chromogenic in situ hybridization (CISH): an alternative and practical method. Bhargava R; Oppenheimer O; Gerald W; Jhanwar SC; Chen B Diagn Mol Pathol; 2005 Jun; 14(2):72-6. PubMed ID: 15905689 [TBL] [Abstract][Full Text] [Related]
27. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification. Spitz R; Hero B; Skowron M; Ernestus K; Berthold F Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958 [TBL] [Abstract][Full Text] [Related]
28. Comparative genomic hybridization study of primary neuroblastoma tumors. United Kingdom Children's Cancer Study Group. Lastowska M; Nacheva E; McGuckin A; Curtis A; Grace C; Pearson A; Bown N Genes Chromosomes Cancer; 1997 Mar; 18(3):162-9. PubMed ID: 9071568 [TBL] [Abstract][Full Text] [Related]
29. Clinical Significance of Segmental Chromosomal Aberrations in Patients with Neuroblastoma: First Report in Korean Population. Lim H; Son MH; Hyun JK; Cho HW; Ju HY; Lee JW; Yoo KH; Sung KW; Koo HH J Korean Med Sci; 2020 Apr; 35(14):e82. PubMed ID: 32281311 [TBL] [Abstract][Full Text] [Related]
30. The genetic and clinical significance of MYCN gain as detected by FISH in neuroblastoma. Souzaki R; Tajiri T; Teshiba R; Higashi M; Kinoshita Y; Tanaka S; Taguchi T Pediatr Surg Int; 2011 Mar; 27(3):231-6. PubMed ID: 21046119 [TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of DNA di-tetraploidy in neuroblastoma. Ladenstein R; Ambros IM; Pötschger U; Amann G; Urban C; Fink FM; Schmitt K; Jones R; Slociak M; Schilling F; Ritter J; Berthold F; Gadner H; Ambros PF Med Pediatr Oncol; 2001 Jan; 36(1):83-92. PubMed ID: 11464912 [TBL] [Abstract][Full Text] [Related]
32. Detection of MYCN gene amplification in neuroblastoma by fluorescence in situ hybridization: a pediatric oncology group study. Mathew P; Valentine MB; Bowman LC; Rowe ST; Nash MB; Valentine VA; Cohn SL; Castleberry RP; Brodeur GM; Look AT Neoplasia; 2001; 3(2):105-9. PubMed ID: 11420745 [TBL] [Abstract][Full Text] [Related]
33. Application of the FISH method and high-density SNP arrays to assess genetic changes in neuroblastoma-research by one institute. Winnicka D; Skowera P; Stelmach M; Styka B; Lejman M Acta Biochim Pol; 2024; 71():12821. PubMed ID: 39049899 [TBL] [Abstract][Full Text] [Related]
34. Comparative genomic hybridization analysis of human neuroblastomas: detection of distal 1p deletions and further molecular genetic characterization of neuroblastoma cell lines. Van Roy N; Jauch A; Van Gele M; Laureys G; Versteeg R; De Paepe A; Cremer T; Speleman F Cancer Genet Cytogenet; 1997 Sep; 97(2):135-42. PubMed ID: 9283597 [TBL] [Abstract][Full Text] [Related]
35. Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas. Ambros PF; Ambros IM; Kerbl R; Luegmayr A; Rumpler S; Ladenstein R; Amann G; Kovar H; Horcher E; De Bernardi B; Michon J; Gadner H Med Pediatr Oncol; 2001 Jan; 36(1):1-4. PubMed ID: 11464855 [TBL] [Abstract][Full Text] [Related]
36. Rearrangement in the coding region of the MYCN gene in a subset of amplicons in a case of neuroblastoma with MYCN amplification. Chen B; Jhanwar SC; Ladanyi M Diagn Mol Pathol; 2001 Jun; 10(2):100-4. PubMed ID: 11385318 [TBL] [Abstract][Full Text] [Related]
37. MYCN gene amplification. Identification of cell populations containing double minutes and homogeneously staining regions in neuroblastoma tumors. Yoshimoto M; Caminada De Toledo SR; Monteiro Caran EM; de Seixas MT; de Martino Lee ML; de Campos Vieira Abib S; Vianna SM; Schettini ST; Anderson Duffles Andrade J Am J Pathol; 1999 Nov; 155(5):1439-43. PubMed ID: 10550298 [TBL] [Abstract][Full Text] [Related]
38. Event-free survival in neuroblastoma with MYCN amplification and deletion of 1p or 11q may be associated with altered immune status. Wei Z; Gong B; Li X; Chen C; Zhao Q BMC Cancer; 2024 Oct; 24(1):1279. PubMed ID: 39407175 [TBL] [Abstract][Full Text] [Related]
39. [Methods of detection and prognostic significance of genetic material increase of the short arm of chromosome 2 and a deletion of the short arm of chromosome 1 in patients with neuroblastoma]. Druĭ AE; Tsaur GA; Shorikov EV; Popov AM; Plekhanova OM; Typonogov SN; Savel'ev LI; Tsvirenko SV; Fechina LG Vopr Onkol; 2013; 59(5):591-8. PubMed ID: 24260886 [TBL] [Abstract][Full Text] [Related]
40. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome. Brinkschmidt C; Christiansen H; Terpe HJ; Simon R; Lampert F; Boecker W; Dockhorn-Dworniczak B Med Pediatr Oncol; 2001 Jan; 36(1):11-3. PubMed ID: 11464859 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]